- Home
- ENX vs TLSI Comparison
ENX vs TLSI Comparison
Compare ENX & TLSI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ENX
- TLSI
- Stock Information
- Founded
- ENX 2002
- TLSI 2010
- Country
- ENX United States
- TLSI United States
- Employees
- ENX N/A
- TLSI N/A
- Industry
- ENX Finance/Investors Services
- TLSI Medical Specialities
- Sector
- ENX Finance
- TLSI Health Care
- Exchange
- ENX Nasdaq
- TLSI Nasdaq
- Market Cap
- ENX 173.1M
- TLSI 158.0M
- IPO Year
- ENX N/A
- TLSI N/A
- Fundamental
- Price
- ENX $9.69
- TLSI $5.77
- Analyst Decision
- ENX
- TLSI Strong Buy
- Analyst Count
- ENX 0
- TLSI 6
- Target Price
- ENX N/A
- TLSI $11.75
- AVG Volume (30 Days)
- ENX 25.4K
- TLSI 40.4K
- Earning Date
- ENX 01-01-0001
- TLSI 03-27-2025
- Dividend Yield
- ENX 3.94%
- TLSI N/A
- EPS Growth
- ENX N/A
- TLSI N/A
- EPS
- ENX 0.16
- TLSI N/A
- Revenue
- ENX N/A
- TLSI $26,891,000.00
- Revenue This Year
- ENX N/A
- TLSI $61.29
- Revenue Next Year
- ENX N/A
- TLSI $53.21
- P/E Ratio
- ENX $61.00
- TLSI N/A
- Revenue Growth
- ENX N/A
- TLSI 67.90
- 52 Week Low
- ENX $7.84
- TLSI $3.50
- 52 Week High
- ENX $10.07
- TLSI $10.42
- Technical
- Relative Strength Index (RSI)
- ENX 51.97
- TLSI 68.94
- Support Level
- ENX $9.63
- TLSI $5.40
- Resistance Level
- ENX $9.77
- TLSI $5.82
- Average True Range (ATR)
- ENX 0.09
- TLSI 0.24
- MACD
- ENX -0.00
- TLSI 0.01
- Stochastic Oscillator
- ENX 37.04
- TLSI 89.19
About ENX Eaton Vance New York Municipal Bond Fund of Beneficial Interest $.01 par value
Eaton Vance New York Municipal Bond Fund is principally engaged in managing investment funds and providing investment management and advisory services to high-net-worth individuals and institutions. It is a non-diversified, closed-end investment company. Its objective is to provide current income exempt from regular federal income tax, including alternative minimum tax, and, in state specific funds, taxes in specified state.
About TLSI TriSalus Life Sciences Inc.
TriSalus Life Sciences Inc is engaged in the research, development, and sales of innovative drug delivery technology and immune-oncology therapeutics to improve outcomes in difficult-to-treat liver and pancreatic cancer. It is developing and marketing two product lines Pressure Enabled Drug Delivery (PEDD) infusion systems, in use today, and an investigational agent, nelitolimod (SD-101), which shows potential to enhance immune system response in the treatment of hepatocellular cancer, pancreatic cancer and other liver solid tumors. TriNav is the newest therapy delivery device with SmartValve technology for the proprietary PEDD approach.